Search results
Results from the WOW.Com Content Network
The low-density lipoprotein receptor (LDL-R) is a mosaic protein of 839 amino acids (after removal of 21-amino acid signal peptide) [5] that mediates the endocytosis of cholesterol-rich low-density lipoprotein (LDL).
[8] [10] [11] As a member of the LDLR family, LRP1 contains cysteine-rich complement-type repeats, EGF (gene) repeats, β-propeller domains, a transmembrane domain, and a cytoplasmic domain. [9] The extracellular domain of LRP1 is the alpha-chain, which comprises four ligand -binding domains (numbered I-IV) containing two, eight, ten, and ...
An antibody–drug conjugate consists of 3 components: [30] [31] Antibody - targets the cancer cell surface and may also elicit a therapeutic response. Payload - elicits the desired therapeutic response. Linker - attaches the payload to the antibody and should be stable in circulation only releasing the payload at the desired target.
There was an average BSA of 1.73 m 2 for 3,000 cancer patients from 1990 to 1998 in a European Organisation for Research and Treatment of Cancer (EORTC) database. [19] During 2005 there was an average BSA of 1.79 m 2 for 3,613 adult cancer patients in the UK. Among them the average BSA for men was 1.91 m 2 and for women was 1.71 m 2. [20]
Secondary antibodies are especially efficient in immunolabeling. Secondary antibodies bind to primary antibodies, which are directly bound to the target antigen(s). In immunolabeling, the primary antibody's Fab domain binds to an antigen and exposes its Fc domain to secondary antibody. Then, the secondary antibody's Fab domain binds to the ...
Bi-specific T-cell engager (BiTE) is a class of artificial bispecific monoclonal antibodies that are investigated for use as anti-cancer drugs. They direct a host's immune system, more specifically the T cells ' cytotoxic activity, against cancer cells.
Biological response modifiers (BRMs) are substances that modify immune responses.They can be endogenous (produced naturally within the body) or exogenous (as pharmaceutical drugs), and they can either enhance an immune response or suppress it.
In the late 1990s and early 2000s, clinical trials with chemically linked Fabs were conducted for the treatment of various types of cancer. Early results were promising, [3] [4] but the concept was dropped because of high production costs. [5] Bi-specific T-cell engagers employ a similar mechanism of action while being cheaper.